A Systematic Review and Meta-Analysis of Clinical Outcomes of Intravitreal Anti-VEGF Agent Treatment Immediately after Cataract Surgery for Patients with Diabetic Retinopathy
Authors:
Open Access
- 16 April 2019
- journal article
- review article
- Published by Wiley in Journal of Ophthalmology
- Vol. 2019, 1-10
Abstract
Aims. To examine possible benefits of intravitreal anti-vascular endothelial growth factor (VEGF) agent treatment immediately after cataract surgery for patients with diabetic retinopathy (DR). Methods. A comprehensive literature search was performed using the Cochrane collaboration methodology to identify randomized controlled trials (RCTs) and comparative studies of cataract surgery with or without anti-VEGF agent treatment for any diabetic retinopathy. Meta-analyses were performed for clinical outcome parameters including changes in macular thickness (MT), best-corrected visual acuity (BCVA), incidence of diabetic retinopathy and maculopathy progression, laser treatment rate, and other complications. Results. Nine RCTs and 3 nonrandomized comparative studies were identified and used for comparing cataract surgery with intravitreal bevacizumab (IVB) or intravitreal ranibizumab (IVR) treatment (338 eyes, intervention group) to cataract surgery alone (329 eyes, control group). Analysis of all data showed that the mean BCVA at 1 week postoperatively had no statistically significant difference in the two groups, but at 1, 3, and 6 months postoperatively, the mean BCVA was statistically significantly better in the anti-VEGF treatment group than that in cataract surgery alone group. Analysis of all data showed that the mean MT was statistically significantly less in the anti-VEGF treatment group at 1 week and 1, 3, and 6 months postoperatively (, , , and , respectively); but postoperative clinical outcomes were differentiated from the type of anti-VEGF agents, IVB or IVR, and the existing macular edema preoperatively. Intravitreal anti-VEGF agent treatment statistically significantly reduced the incidence of diabetic retinopathy progression and maculopathy progression compared to the control group (, , respectively). Conclusion. IVB or IVR treatment immediately after cataract surgery may represent a safe and effective strategy to prevent postoperative macular thickening or reduce macular edema and result in greater mean improvements in visual acuity for diabetic patients.
Keywords
This publication has 32 references indexed in Scilit:
- Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysisCochrane Database of Systematic Reviews, 2017
- Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular EdemaOphthalmology, 2016
- Diabetic Macular Edema at the time of Cataract Surgery trial: a prospective, randomized clinical trial of intravitreous bevacizumab versus triamcinolone in patients with diabetic macular oedema at the time of cataract surgery – preliminary 6 month resultsClinical & Experimental Ophthalmology, 2016
- Aqueous Cytokines as Predictors of Macular Edema in Patients with Diabetes following Uncomplicated Phacoemulsification Cataract SurgeryBioMed Research International, 2015
- Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macular oedema: a systematic reviewBritish Journal of Ophthalmology, 2011
- Aqueous Vascular Endothelial Growth Factor as a Predictor of Macular Thickening Following Cataract Surgery in Patients With Diabetes MellitusAmerican Journal of Ophthalmology, 2009
- Analysis of Macular Edema after Cataract Surgery in Patients with Diabetes Using Optical Coherence TomographyOphthalmology, 2007
- Diabetic cataract removal: postoperative progression of maculopathy--growth factor and clinical analysisBritish Journal of Ophthalmology, 2006
- Prediction of macular edema exacerbation after phacoemulsification in patients with nonproliferative diabetic retinopathyJournal of Cataract & Refractive Surgery, 2002
- A prospective, case controlled study of the natural history of diabetic retinopathy and maculopathy after uncomplicated phacoemulsification cataract surgery in patients with type 2 diabetesBritish Journal of Ophthalmology, 2002